Back to search

National and Kapodistrian University of Athens

Μελέτη της έκφρασης του CFTR γονιδίου σε μεταλλάξεις ματίσματος (splicing mutations)

Abstract

dc:description

The effects of eight splicing mutations, one nonsense and 2 missense mutations on Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene expression, were investigated by RT-PCR analysis of mRNA extracted from nasal epithelial cells harvested from patients harbouring the mutations. We studied 4 subjects with c.621+3A>G, one with c.2751+2T>A, one with c.296+1G>C, one with c.1898+1G>T, seven with 3120+1G>A, 3 with 1525-1G>A, eighteen with 2789+5G>A, 7 with c.711+3A>G, five with p.E822X, 7 with p.D565G and one with p.G576A and compared the results to CFTR mRNA from normal subjects. Our results show that mutations c.621+3A>G, c.2751+2T>A, c.296+1G>C, c.1898+1G>A, c.3120+1G>A that disrupt the 5’ splice donor sites of introns 4, 14a, 2, 12 and 16 respectively, and c.1525-1G>A, which disrupts the 3’ splice acceptor site of intron 9 and nonsense p.E822X all result in severe deficiency of normal CFTR mRNA. The patients with severe mutations have severe clinical phenotype with both the pancreatic and pulmonary function affected. While mutations c.2789+5G>A and c.711+3A>G result in moderate deficiency of normal CFTR mRNA and therefore milder phenotype in the patients. Finally the two missense mutations p.D565G and p.G576A also result in the production of aberrantly spliced mRNA in nasal epithelial cells lacking exon 12, by affecting the exonic splicing enhancer sequences of the exon. The effect of single nucleotide substitutions on ESE/ESS cannot be accurately predicted by either SR matrices or enhancer identification. The recognition and characterization of splicing abnormalities, caused by exon sequence variations on regulatory elements, may represent a frequent disease-causing mechanism that also relates to the phenotypic variability. This information is especially useful for phenotype prediction of patients harbouring the above mutations and for genetic counselling. By characterizing the major aberrantly splicing products of the above mutations we could design oligomeric junction probes for hybridization of sequences: exon–exon (normal); exon n-exon n+2 (skipping of 1 exon); and additional oligomeric probes covering cases where the aberrant transcript includes part of an exon or intron sequences. The CF-splicing CHIP will be developed on the NanoChip® 400 Molecular Biology Workstation which should offer accurate and rapid detection of any splicing abnormality on cDNA products of CF patients.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2007

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Tsiamouri, Alexia
  • Τσιαμούρη, Αλεξία

Subjects

dc:subject × 21

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/23641

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Tsiamouri, Alexia; Τσιαμούρη, Αλεξία. Μελέτη της έκφρασης του CFTR γονιδίου σε μεταλλάξεις ματίσματος (splicing mutations). National and Kapodistrian University of Athens, 2007. http://hdl.handle.net/10442/hedi/23641